Loading...
Loading...
IMVT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 94.2M |
| Operating I/L | -94.3M |
| Other Income/Expense | 7.2M |
| Interest Income | 7.2M |
| Pretax | -87.1M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -87.2M |
Immunovant, Inc. is a clinical-stage biopharmaceutical company specializing in the development of monoclonal antibodies for the treatment of autoimmune diseases. Their flagship product, batoclimab, is a fully human monoclonal antibody designed to selectively bind to and inhibit the neonatal fragment crystallizable receptor. Currently, batoclimab is undergoing Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials initiated for warm autoimmune hemolytic anemia. As a subsidiary of Roivant Sciences Ltd., Immunovant, Inc. focuses on the development and commercialization of innovative therapies to address unmet medical needs in the autoimmune disease space.
